Articles by Steven R. Goldstein

1 2 3 4 5

Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause...

Manson, JoAnn E.; Ames, Jeffrey M.; Shapiro, Marla; More

Menopause. 22(3):247-253, March 2015.

Why the product labeling for low-dose vaginal estrogen should be changed

Manson, JoAnn E.; Goldstein, Steven R.; Kagan, Risa; More

Menopause. 21(9):911-916, September 2014.

Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass

Goldstein, Steven R.; Bhattoa, Harjit Pal; Neven, Patrick; More

Menopause. 19(1):41-47, January 2012.

Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes

Goldstein, Steven R.; Neven, Patrick; Cummings, Steven; More

Menopause. 18(1):17-22, January 2011.

Endometrial safety: a key hurdle for selective estrogen receptor modulators in development

Pinkerton, JoAnn V.; Goldstein, Steven R.

Menopause. 17(3):642-653, May-June 2010.

Raloxifene use in clinical practice: efficacy and safety

Goldstein, Steven R.; Duvernoy, Claire S.; Calaf, Joaquim; More

Menopause. 16(2):413-421, March 2009.

Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen

Goldstein, Steven R.; Johnson, Susan; Watts, Nelson B.; More

Menopause. 12(2):160-164, March-April 2005.

The case for less-than-monthly progestogen in women on HT: is transvaginal ultrasound the key?

Goldstein, Steven R.

Menopause. 12(1):110-113, January-February 2005.

1 2 3 4 5